Dudediligence.

Lyell Immunopharma, Inc

LYELNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$34,000Sep ’24$11,000Dec ’24$7,000Mar ’25$8,000Jun ’25$15,000Sep ’25$6,000Dec ’25$2,000Mar ’26$4,000Jun ’26
Net income, by quarter
−$44.6MSep ’24−$191.9MDec ’24−$52.2MMar ’25−$42.7MJun ’25−$38.8MSep ’25−$140.7MDec ’25−$24.2MMar ’26−$44.8MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$10.7M$84.7M$130,000$61,000$36,000
Operating income−$214.8M−$187.1M−$247.0M−$358.8M−$269.4M
Net income−$250.2M−$183.1M−$234.6M−$343.0M−$274.4M
Operating cash flow−$126.2M−$169.6M−$163.7M−$162.4M−$150.0M
Free cash flow−$191.8M−$193.8M−$166.4M−$162.9M−$150.8M
Cash$293.8M$123.6M$145.6M$105.6M$60.2M
Shares outstanding242.7M249.6M254.0M14.7M21.3M